Early Phase 1 Kidney Cancer Trial, Recruiting NCT03810651 Sponsor: Children's Hospital of Philadelphia Condition: Kidney Cancer
Back to Kidney Cancer

Early Phase 1 Kidney Cancer Trial, Recruiting

NCT03810651
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are under 30 years of age
  • People who have been diagnosed with Wilms tumor or clear cell sarcoma of the kidney (a type of kidney cancer) where radiation therapy is considered a standard part of treatment
  • People whose Wilms tumor is classified as "favorable histology, stage III" (a specific cancer type and stage classification — confirm with trial site)
  • People whose Wilms tumor involves a pattern called focal or diffuse anaplasia (an abnormal cell appearance — confirm with trial site)
  • People diagnosed with clear cell sarcoma of the kidney (CCSK)
  • People whose treating doctor has determined that external beam radiation therapy (a type of radiation treatment delivered from outside the body) is appropriate as standard care for their kidney cancer

Who may not be able to join:

  • People who have previously received radiation therapy to the area of the body affected by the cancer being studied
  • People who have already received chemotherapy for their Wilms tumor or clear cell sarcoma of the kidney diagnosis
  • People who are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Christine Hill-Kayser, MD, Children's Hospital of Philadelphia

Phone: 215-590-2810

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Children's Hospital of Philadelphia
Registry
ClinicalTrials.gov
Start date
26 December 2017
Est. completion
30 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Occurrence of any non-hematologic toxicity that occurs within 90 days following the start of proton therapy assessed with with NCI Common toxicity criteria (CTC Version 4.0) grades].

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov